Literature DB >> 30318013

Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions.

Ricardo Jorge Dinis-Oliveira1,2,3, Carolina Lança Pereira1, Diana Dias da Silva1,2.   

Abstract

BACKGROUND: Mescaline (3,4,5-trimethoxyphenethylamine), mainly found in the Peyote cactus (Lophophora williamsii), is one of the oldest known hallucinogenic agents that influence human and animal behavior, but its psychoactive mechanisms remain poorly understood.
OBJECTIVES: This article aims to fully review pharmacokinetics and pharmacodynamics of mescaline, focusing on the in vivo and in vitro metabolic profile of the drug and its implications for the variability of response.
METHODS: Mescaline pharmacokinetic and pharmacodynamic aspects were searched in books and in PubMed (U.S. National Library of Medicine) without a limiting period. Biological effects of other compounds found in peyote were also reviewed.
RESULTS: Although its illicit administration is less common, in comparison with cocaine and Cannabis, it has been extensively described in adolescents and young adults, and licit consumption often occurs in religious and therapeutic rituals practiced by the Native American Church. Its pharmacodynamic mechanisms of action are primarily attributed to the interaction with the serotonergic 5-HT2A-C receptors, and therefore clinical effects are similar to those elicited by other psychoactive substances, such as lysergic acid diethylamide (LSD) and psilocybin, which include euphoria, hallucinations, depersonalization and psychoses. Moreover, as a phenethylamine derivative, signs and symptoms are consistent with a sympathomimetic effect. Mescaline is mainly metabolized into trimethoxyphenylacetic acid by oxidative deamination but several minor metabolites with possible clinical and forensic repercussions have also been reported.
CONCLUSION: Most reports concerning mescaline were presented in a complete absence of exposure confirmation, since toxicological analysis is not widely available. Addiction and dependence are practically absent and it is clear that most intoxications appear to be mild and are unlikely to produce lifethreatening symptoms, which favors the contemporary interest in the therapeutic potential of the drugs of the class. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Mescaline; metabolism; peyote; pharmacodynamics; pharmacokinetics; toxicity.

Mesh:

Substances:

Year:  2019        PMID: 30318013      PMCID: PMC6864602          DOI: 10.2174/1874467211666181010154139

Source DB:  PubMed          Journal:  Curr Mol Pharmacol        ISSN: 1874-4672            Impact factor:   3.339


  90 in total

1.  What geometric visual hallucinations tell us about the visual cortex.

Authors:  Paul C Bressloff; Jack D Cowan; Martin Golubitsky; Peter J Thomas; Matthew C Wiener
Journal:  Neural Comput       Date:  2002-03       Impact factor: 2.026

2.  Methylation and demethylation in relation to the in vitro metabolism of mescaline.

Authors:  J DALY; J AXELROD; B WITKOP
Journal:  Ann N Y Acad Sci       Date:  1962-01-13       Impact factor: 5.691

3.  A further note on the mechanism of the antidotal action of sodium succinate in the mescaline psychosis.

Authors:  I STEVENSON; L C MOKRASCH
Journal:  Am J Psychiatry       Date:  1958-05       Impact factor: 18.112

4.  [Mescaline and the San Pedro cactus ritual: archaeological and ethnographic evidence in northern Peru].

Authors:  F J Carod-Artal; C B Vázquez-Cabrera
Journal:  Rev Neurol       Date:  2006 Apr 16-30       Impact factor: 0.870

5.  Dihydrobenzofuran analogues of hallucinogens. 4. Mescaline derivatives.

Authors:  A P Monte; S R Waldman; D Marona-Lewicka; D B Wainscott; D L Nelson; E Sanders-Bush; D E Nichols
Journal:  J Med Chem       Date:  1997-09-12       Impact factor: 7.446

6.  Hallucinogens of plant origin.

Authors:  R E Schultes
Journal:  Science       Date:  1969-01-17       Impact factor: 47.728

7.  Metabolic fate of mescaline in man.

Authors:  K D Charalampous; K E Walker; J Kinross-Wright
Journal:  Psychopharmacologia       Date:  1966

8.  Interactions of amphetamine analogs with human liver CYP2D6.

Authors:  D Wu; S V Otton; T Inaba; W Kalow; E M Sellers
Journal:  Biochem Pharmacol       Date:  1997-06-01       Impact factor: 5.858

9.  Mescaline-induced psychopathological, neuropsychological, and neurometabolic effects in normal subjects: experimental psychosis as a tool for psychiatric research.

Authors:  L Hermle; M Fünfgeld; G Oepen; H Botsch; D Borchardt; E Gouzoulis; R A Fehrenbach; M Spitzer
Journal:  Biol Psychiatry       Date:  1992-12-01       Impact factor: 13.382

10.  Receptor interaction profiles of novel psychoactive tryptamines compared with classic hallucinogens.

Authors:  Anna Rickli; Olivier D Moning; Marius C Hoener; Matthias E Liechti
Journal:  Eur Neuropsychopharmacol       Date:  2016-05-20       Impact factor: 4.600

View more
  6 in total

Review 1.  Psychedelics in the treatment of unipolar and bipolar depression.

Authors:  Oliver G Bosch; Simon Halm; Erich Seifritz
Journal:  Int J Bipolar Disord       Date:  2022-07-05

2.  Cellular Uptake of Psychostimulants - Are High- and Low-Affinity Organic Cation Transporters Drug Traffickers?

Authors:  Ole Jensen; Muhammad Rafehi; Lukas Gebauer; Jürgen Brockmöller
Journal:  Front Pharmacol       Date:  2021-01-20       Impact factor: 5.810

3.  Evaluation of the cytotoxic and immunogenic potential of temozolamide, panobinostat, and Lophophora williamsii extract against C6 glioma cells.

Authors:  Moisés Armides Franco-Molina; Silvia Elena Santana-Krímskaya; Luis Mario Madrigal-de-León; Erika Evangelina Coronado-Cerda; Diana Ginette Zárate-Triviño; Sara Paola Hernández-Martínez; Paola Leonor García-Coronado; Cristina Rodríguez-Padilla
Journal:  EXCLI J       Date:  2021-03-09       Impact factor: 4.068

Review 4.  Pharmacokinetics and Pharmacodynamics of Salvinorin A and Salvia divinorum: Clinical and Forensic Aspects.

Authors:  Andreia Machado Brito-da-Costa; Diana Dias-da-Silva; Nelson G M Gomes; Ricardo Jorge Dinis-Oliveira; Áurea Madureira-Carvalho
Journal:  Pharmaceuticals (Basel)       Date:  2021-02-03

5.  Exploring protective associations between the use of classic psychedelics and cocaine use disorder: a population-based survey study.

Authors:  Grant M Jones; Matthew K Nock
Journal:  Sci Rep       Date:  2022-02-16       Impact factor: 4.996

Review 6.  Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain.

Authors:  Elaine Meade; Sarah Hehir; Neil Rowan; Mary Garvey
Journal:  J Fungi (Basel)       Date:  2022-03-11
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.